Obicetrapib · RUBENS
NewAmsterdam guides to RUBENS topline data by year-end 2026 and reconfirmed it as ongoing in September. European approval supported by BROADWAY/BROOKLYN/TANDEM does not answer RUBENS. obicetrapib — phase 3 study in Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS). NCT07219602 measures The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group (84 days). Registry status: active not recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- European approval has already occurred; it must not be presented as a pending RUBENS trial outcome.
Primary evidence
Sponsor expectation: by year-end 2026 — day unconfirmed
Potential outcome market
Will obicetrapib meet the prespecified primary endpoint in NCT07219602 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.